Engflag

Spiramin

Quick links to important sections

Spiramin

Spiramin_EN

Method of action: Bacteriostatic

Treatment option: Abscess, Asthma, Bronchitis, Sexually Transmitted Diseases, Community Acquired Pneumonia, Impetigo, Pertussis, Meningitis, Pneumonia, Prostatitis

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Spiramin

What is Spiramin?

Spiramin is a pharmaceutical preparation containing the active compound Spiramycin, which is classified as a macrolide antibiotic and an antimicrobial agent. This medication belongs to a class of agents whose general purpose is to combat infections caused by susceptible microorganisms. Spiramycin is recognized for its specific application in managing certain infectious conditions based on its established pharmacological profile.

Composition, Origin, and Available Forms

The active substance, Spiramycin, is a natural product chemically derived from the culture of the bacterium Streptomyces ambofaciens. The active components are a complex mixture, primarily consisting of Spiramycin I, Spiramycin II, and Spiramycin III. The drug is supplied as a single-ingredient product in various dosage forms, including oral formulations such as tablets or capsules, and parenteral formulations intended for intravenous administration. This dual availability allows the medicine to be used systemically, such as beginning with an injection in a clinical setting before transitioning to an oral formulation for the continuation of treatment.

Spiramin's Function: High-Level Purpose

The fundamental function of Spiramycin is to inhibit the growth and reproduction of susceptible infectious agents, categorizing it as an antimicrobial agent. This is achieved through its action as an inhibitor of bacterial protein synthesis. Specifically, the compound targets and binds to the 50S ribosomal subunit within the microorganism. By preventing the microbe from manufacturing the proteins it requires to grow and divide, the medicine exerts a bacteriostatic effect. The core purpose of the medicine is to interrupt the proliferation of infectious agents to assist in the management of the microbial condition.

Regulatory References

  1. Macrolides Antibiotics Review

What side effects are possible with Spiramin?

Possible Side Effects and Safety Information

The regulatory safety profile for Spiramin (spiramycin) categorizes documented adverse reactions primarily by frequency and the body system affected. These classifications ensure transparency regarding the potential risks associated with the medicine, based strictly on official regulatory labeling.

Frequency-Classified Adverse Reactions

Adverse reactions are formally ranked according to their incidence in clinical data and post-marketing surveillance:

Frequency Category Associated Adverse Reactions
Common ( ge 1/100 to <1/10) Gastrointestinal disturbances, including nausea, vomiting, diarrhea, and abdominal pain
Uncommon ( ge 1/1,000 to <1/100) Headache, dizziness, rash, and transient paraesthesia (tingling)
Rare ( ge 1/10,000 to <1/1,000) Cholestatic hepatitis and abnormal liver function tests
Not Known Severe cutaneous and cardiac events, including anaphylactic shock

Safety Constraints and Serious Reactions

Official labeling documents specific serious adverse reactions and conditions that restrict the use of Spiramin.

Serious Adverse Reactions

Serious, rare reactions officially documented include potentially life-threatening cardiac events like QT interval prolongation and ventricular arrhythmias. Severe skin disorders, such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Acute Generalized Exanthematous Pustulosis (AGEP), are also documented as serious but rare concerns.

Population-Specific Safety Constraints

Spiramin is formally contraindicated in patients with a known congenital prolonged QT interval. Use is also restricted in individuals with severe hepatic impairment and those with uncorrected hypokalaemia or hypomagnesaemia due to the increased risk of cardiac adverse effects. These constraints define specific patient populations where the medicine should not be used.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information on Spiramin (Spiramycin) overdose is based strictly on descriptions found within official government regulatory documents and prescribing information.

Documented Overdose Manifestations

Classification Aspect Official Regulatory Statement
Common Presentations Abdominal discomfort, nausea, and diarrhea are the common symptoms documented, particularly following oral doses exceeding 4 grams per day.
Serious Outcomes The most serious risk is the potential for QT prolongation, a cardiac rhythm disturbance that may result in fast or irregular heartbeat. This outcome may rarely be fatal.

Emergency Actions Mandated by Regulators

Action Area Official Regulatory Statement
Required Response Suspected overdosage mandates immediate contact with a healthcare professional, hospital emergency department, or regional poison control centre, even if the patient is asymptomatic.
Urgent Medical Help Immediate medical help is required for severe symptoms such such as fainting/passing out, severe dizziness, or trouble breathing; emergency services must be called for these manifestations.
Management Strategy No specific treatment has been proposed (no known antidote). Management is strictly symptomatic and supportive.

The official overdose profile separates common gastrointestinal symptoms from the rare but life-threatening cardiac risks, establishing clear, mandatory help-seeking conditions for both asymptomatic suspicion and severe clinical signs.

Therapeutic Uses of Spiramin

What Spiramin Treats: Main Uses and Benefits

Spiramin (spiramycin) is a macrolide antibiotic used in the management of infections caused by susceptible bacteria and parasites. This medication is used in the treatment of conditions affecting the respiratory tract (such as certain pneumonias), the buccal cavity (mouth), skin, and soft tissues when caused by susceptible organisms.

Spiramycin is also administered for the management of toxoplasmosis in pregnant patients. It is also used for the treatment of certain sexually transmitted infections, including gonorrhea, in specific patient populations. It is intended to support the management of symptoms associated with these infections.

“The therapeutic application of spiramycin focuses on treating infections of multiple body systems, and may assist with symptom management where susceptible bacteria are present.”

Quick Fact: Used for Bacterial and Parasitic Infections

Regulatory References

  1. Health Canada Product Monograph for Rovamycine

Eligibility and Restrictions for Use

The eligibility for Spiramin (Spiramycin) is determined by regulatory-defined contraindications, patient age, organ function, and physiological state.

Contraindications and Restrictions

Category Official Regulatory Statement
Contraindicated Populations The medicine is strictly contraindicated for patients with a known hypersensitivity or allergy to spiramycin or any other macrolide antibiotic.
Ineffective Use Spiramin must not be used for patients with meningitis, as the drug does not achieve sufficient concentrations in the cerebrospinal fluid for efficacy.
Organ Function Caution is advised for patients with pre-existing liver disease or obstruction of the bile ducts, as these conditions may increase the chance of side effects.

Age and Physiological Eligibility

  • Age Groups: Use is established for adults and children. While use in older adults is permitted, official documents note limited specific data comparing its use in this population with younger adults.
  • Pregnancy: Spiramin is specifically permitted for the management of toxoplasmosis in pregnant patients to reduce the risk of transmission to the fetus. This is a unique, condition-specific allowance.
  • Lactation: As with other macrolides, Spiramycin is excreted in breast milk. Official guidance generally advises caution or restriction, and specific label advice must be followed.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Spiramin (spiramycin) has officially documented interaction patterns based on regulatory prescribing information. These interactions are categorized by their effects on drug exposure and shared physiological risk, rather than general safety or usage.

Documented Drug–Drug Interactions

Pharmacodynamic Interaction (Cardiac Risk) The active substance may cause prolongation of the QT interval. Co-administration with other QT-prolonging medicinal products, such as Class IA and III antiarrhythmics, increases the additive risk of ventricular arrhythmias, establishing a regulatory caution.

Exposure-Altering Interaction (Absorption) Spiramin is documented to interfere with the absorption of Carbidopa, leading to decreased plasma levels of co-administered Levodopa. This effect is classified as an absorption-based interaction.

Drug–Food and Administration Constraints

Food Interaction Rule Official regulatory documents include an administration-timing rule stating that oral formulations are best taken on an empty stomach. This constraint is necessary due to documented effects of food on Spiramin's absorption.

Population Considerations The risk associated with the QT prolongation interaction is noted to be greater in patients with pre-existing cardiac conditions or uncorrected electrolyte imbalances. Additionally, patients with liver disease may experience altered drug clearance, which can heighten the risk profile of co-administered medicines.

Mechanism of Action

Targeting Bacterial Protein Synthesis

Spiramin works as a highly selective inhibitor by binding non-covalently to the 50S ribosomal subunit within susceptible bacteria. This targeted attachment occurs at the 23S ribosomal RNA component, situated within the exit tunnel. The molecule's presence physically obstructs the crucial process of peptidyl-tRNA translocation, immediately halting the elongation of the polypeptide chain. This interference prevents the microbe from synthesizing the essential structural and enzymatic proteins required for its growth and function. The resulting state of bacteriostasis (growth arrest) prevents the proliferation of the microbial population, shifting the physiological balance toward host defense.

️ Mechanisms Limiting Efficacy

The efficacy of this inhibitory action is subject to certain biological constraints, primarily resistance mediated by the erm gene. This gene leads to the enzymatic methylation of the 23S ribosomal RNA. This modification structurally changes the drug's binding pocket, preventing Spiramin from effectively attaching to the ribosome and blocking protein synthesis. Consequently, the bacterial cell maintains its capacity for proliferation, exemplifying a biological constraint driven by target site modification.

Dosage and Administration Information

How Spiramin is Used: Official Administration Guidelines

Spiramin (spiramycin) is officially available for Oral, Intravenous (IV), and Rectal administration. The oral forms, which include tablets and capsules, are available in strengths measured in both milligrams (e.g., 500 mg to 1 gram) and International Units (IU).

Standard adult oral dosing ranges typically from 1 to 2 grams daily, and the total daily dose is structured to be taken in two or three separate administrations. For the medicine to maintain consistent levels, it is a high-level scheduling principle that doses are consumed at evenly spaced times throughout the day. Intravenous use is administered in a clinical setting, typically starting at 500 mg every eight hours, and must be delivered via slow injection into a vein.

Official instructions specify particular contextual conditions for use. Oral forms are best taken on an empty stomach but may be taken with food if necessary for tolerability. If the rectal suppository form is used, specific preparation is required: the unit must be removed from the foil and moistened with cold water before insertion. Furthermore, the prescribed treatment must be completed for the full duration, and for certain specific uses, the medicine is administered in alternating cyclic regimens with other agents. In the event of a missed dose, if the next scheduled dose is nearly due, the missed dose should be skipped to avoid a double administration. Dosing for pediatric patients requires a precise, weight-based calculation formula.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy in Condition A

Research has examined the drug’s use in relation to changes in symptoms of Condition A. Studies have compared data for this combination therapy to older treatments.

One study reported observations regarding the onset of symptom change in some participants.

Mechanism of Action

Studies have explored the action of Component B and its potential in laboratory models.

Phase III data suggests that this dosage was associated with observed effects.

Long-term Outcomes

Clinical trials investigated measurements related to disease progression over five years. The findings were mixed regarding the duration of the measured change.

Studies compared the outcomes of this therapy to monotherapy.

Safety Profile

Studies examined the drug's pharmacokinetic properties.

Research has not yet concluded on the drug’s use in individuals with mild liver impairment. The drug was not studied in people with severe kidney issues.

Research is ongoing or unavailable regarding the use of this drug in pediatric populations. Further investigation is necessary to fully characterize the research profile.

How should Spiramin be stored and disposed of?

How to Store and Dispose of Spiramin: Official Regulatory Information

Official regulatory guidelines for Spiramin storage focus on maintaining product integrity. The medicine must be kept protected from light and moisture and should be stored at a temperature that does not exceed 25 C. This ensures stability as defined by regulatory bodies.

For disposal, unused or expired Spiramin should be managed through an official drug take-back program. If this option is unavailable, the product must be rendered unusable by mixing it with an undesirable substance (such as used coffee grounds or dirt) before placing the mixture in a sealed container for household trash disposal. The product must not be released to the environment, and general guidance encourages that unused medicines be removed from the home promptly to mitigate risks, particularly where children are present.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagItaly

Equivalent of Spiramin found in:

A-Z Index: